Logo

Activx Partners with Gilead Sciences

Apr 09, 2004

NEW YORK, April 9 (GenomeWeb News) - Activx Biosciences announced this week that it will apply its activity proteomics technology to characterize the activities of compounds for Foster City, Calif.-based Gilead Sciences.

Activx has similar deals already with Pfizer and Kyorin Pharmaceuticals.

Financial terms of the deal were not disclosed.

 

Breaking News
The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.